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Abstract
Background Angiotensin II receptor blockers (ARBs)
play a key role in hypertension therapy. Recently, fima-
sartan, the ninth ARB, was developed, but its safety and
efficacy have not been well established.
Objective The objective of this study was to determine
whether age, sex, concomitant disease, and current anti-
hypertensive medications affect the safety and efficacy of
fimasartan in patients with arterial hypertension.
Methods This was a large-scale, open-label observational
study to determine the safety and efficacy of fimasartan in
patients with hypertension. Patients who were treated for
more than 2 months with fimasartan (60 or 120 mg, once
daily) were recruited, and the data were systematically
collected using electronic case report forms. Written
informed consent forms were obtained from all patients.
Results A total of 14,151 patients (50.7 % males; mean age
59 ± 12 years) were evaluated, of whom 37.9 % were never
treated with fimasartan, 53.5 % were switched to fimasartan,
and 8.5 % had fimasartan added to their treatment. Overall,
fimasartan reduced systolic blood pressure (SBP) from
145.4 ± 18.1 to 126.8 ± 12.6 mmHg and diastolic blood
pressure (DBP) from 88.7 ± 11.8 to 79.0 ± 8.7 mmHg (all
p \ 0.001). The pulse rate decreased from 74.4 ± 10.3 to
71.9 ± 9.2 beats/min in comparison with before treatment
(p \ 0.001). The reductions were similar between sexes, age
groups, and patients with and without co-morbidities, and
were not dependent on prior or concomitant treatment with
other antihypertensive drugs. Adverse events were reported
in 3.31 % (treatment-emergent) and 2.35 % (drug-related) of
patients; there were no dose differences for adverse events.
The most frequent adverse events were dizziness (1.55 %)
and headache (0.52 %); other adverse events were rare. The
responder rate (DBP to \90 mmHg or a reduction of
C10 mmHg) and the goal rate (combined SBP/DBP\140/
90 mmHg) were 85.0 and 75.6 %, respectively. Global drug
compliance was rated as excellent, very good, good, and poor
in 68.1, 26.9, 3.4, and 1.7 % of patients, respectively.
Conclusion The safety, efficacy, and compliance of
fimasartan were found to be excellent in a large patient
population that included patients potentially at higher risk
for adverse events.
1 Introduction
Angiotensin II is the most important molecule in the renin-
angiotensin system. Angiotensin II increases heart contrac-
tions and sodium reabsorption and has harmful effects on
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organs and vessels due to vascular hypertrophy and vaso-
constriction [1]. Restricting the effects of angiotensin II is not
only effective in decreasing blood pressure (BP) but also has
positive effects in preventing and improving heart failure,
renal failure, stroke, and diabetic renal neuropathy [2–4].
Independent from the decrease in BP, angiotensin antagonists
decrease the incidence of cardiovascular events in a hyper-
tensive and high-risk Asian population [5, 6]. For this reason,
angiotensin II antagonists are listed as the initial medication
prescribed for hypertensive patients in the European Society
of Hypertension/European Society of Cardiology (ESH/
ESC) guidelines, and hypertension treatment guidelines of
Japan [7, 8], and are also strongly recommended in some
special circumstances according to the Joint National Com-
mittee (JNC) 7 hypertension guideline [9].
Since the approval of the first ARB, losartan, in 1995, more
ARBs have been developed and are widely used as antihy-
pertensive medications worldwide [10]. All the ARBs are
generally similar in that they have the same goal of restricting
angiotensin II, but each is distinct due to differences in
potency, which vary according to pharmacokinetic profile.
Some direct comparative studies have concluded that the
recently developed ARBs lower BP better than the earlier
ARBs, which may be due to the former’s stronger degree of
binding at the receptor level for a longer period of time [11,
12]. In addition, this difference is known to have additional
effects, such as improving serum lipid levels and glucose
metabolism [13] and lowering serum uric acid levels [14].
Fimasartan [(2-butyl-5-dimethylaminothiocarbonylme-
thyl-6-methyl-3-[[20-(1H-tetrazol-5-yl) biphenyl-4-yl] methyl]
pyrimidin-4(3H)-one); molecular formula, C27H31N7OS;
molecular weight 501.65; formally known as BR-A-657;
Boryung Pharm. Co. Ltd, Seoul, Korea], the ninth ARB, was
approved in September 2010 and was launched in March 2011
in Korea. This drug is a bioisosteric replacement of the
imidazole part of losartan with pyrimidin-4(3H)-one that
provided higher potency and stronger efficacy than losartan
[15, 16] and exhibited a quick onset of antihypertensive effect
during initial Phase II and III clinical trials [17]. The present
study investigated drug safety and efficacy and patient com-
pliance in hypertensive patients who were prescribed fima-
sartan for at least 2 months. In addition, the effects of the
presence of concomitant disease and the application of other




This was an open-label, observational study, in which 726
internal medicine doctors who specialize in primary care in
Korea participated. Among the patients prescribed fima-
sartan for more than 2 months, those who agreed to par-
ticipate in the study were requested to systematically
complete electronic case report forms. This research was
approved by the Institutional Review Board of the Cheil
General Hospital, Kwandong University College of Medi-
cine, and informed consent forms were obtained from all
patients.
2.2 Patients
There were no specific guidelines for the inclusion or
exclusion of patients; however, to be eligible for inclusion
in this study, the patient had to be 18 years or older and
taking fimasartan under doctor’s orders. Patients who were
prescribed fimasartan since its release on 1 March 2011 in
Korea were provided with informed written consent forms
at each clinic, and the data were collected continuously
from 25–30 patients who had been taking the medication at
the approved dose of fimasartan 60 or 120 mg for more
than 2 months. Even patients who had not reached the
2-month duration of treatment were included in the study
for the safety evaluation. The data were collected from a
total of 14,571 patients, and statistical analyses were per-
formed with the exclusion of data from the following:
patients who did not have BP recorded before or after drug
administration, patients who were given an uncommon
dose of the drug (30 or 240 mg), and patients with unclear
sources for their data. Thereafter, 14,151 patients (50.7 %
males; mean age 59 ± 12 years) were analyzed, 37.9 % of
whom were never treated with fimasartan (the naı¨ve
group), 53.5 % of whom were switched to fimasartan (the
switched group), and 8.5 % who had fimasartan added to
their usual treatment (the add-on group). Of these patients,
10,543 patients were treated with 60 mg of fimasartan and
3,608 patients with 120 mg of fimasartan.
2.3 Evaluation
After obtaining a consent form, a questionnaire regarding
patient risk factors, concomitant disease(s), and current
medications was administered. The questionnaire was used
to analyze the effects and the side effects of sex, age,
concomitant disease, and risk factors. The definitions of
various risk factors are as follows: males aged C55 years
and females aged C65 years; smokers who have smoked in
the past 30 days; obesity with a body mass index (BMI)
C25 kg/m2; abdominal obesity with a waist size greater
than 90 cm for males and 80 cm for females; physical
inactivity involving less than 2 h of exercise per week;
diabetes with a fasting blood sugar (FBS) level C126 mg/
dL and/or being treated with medication or insulin; dysli-
pidemia with a low density lipoprotein (LDL)-cholesterol
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level C160 mg/dL, a total (T)-cholesterol level C240 mg/
dL, and a high density lipoprotein (HDL)-cholesterol level
\40 mg/dL for males and \50 mg/dL for females or tak-
ing lipid-lowering medication; and a diagnosis of or pre-
senting signs of sleep apnea as determined by a doctor.
All symptoms that followed drug administration were
recorded, and the relevance to the drug was determined by
the doctors. The efficacy of the drug was initially deter-
mined by the differences in the diastolic (DBP) and systolic
(SBP) BPs before and after drug administration in the
clinic. In addition, the responder rate was defined as a DBP
\90 mmHg or decreased by C10 mmHg, and the goal rate
was defined as a combined SBP/DBP \140/90 mmHg and
\130/80 mmHg in patients with diabetes mellitus and
renal disease, respectively [18]. All patients were asked
about the number of drugs left when they visited the clinic
and compliance was calculated by dividing the actual
number of administrations by the planned number and was
defined as excellent (100 %), very good (90–99 %), good
(80–89 %), and poor (\80 %). For the quality assurance of
the investigation, the coordination center of the Cheil
General Hospital reviewed the entire database and verified
approximately 39 % of the data that was incomplete,
questionable, or reported abnormal reactions.
2.4 Statistics
All statistical analyses were conducted using SAS version
9.2 (SAS Institute Inc., Cary, NC, USA). All participant
data on demographic information, laboratory tests, ECG
results, and medications for hypertension and other con-
ditions are presented after calculating descriptive statistics
for males and females. Abnormal reactions were coded and
organized using the Medical Dictionary for Regulatory
Activities (MedDRA) 10.0, and the frequencies and per-
centages of the participants with abnormal reactions in the
different treatment groups are presented. All abnormal
reactions were organized based on the presence of symp-
toms before and after taking fimasartan and the importance,
severity, relevance, treatment, and termination of the
reaction; abnormal reactions related to fimasartan, serious
reactions, and reactions from incomplete participants were
also noted.
To determine whether there was a difference in the
incidence rate of an adverse event following administration
of various doses of fimasartan, a Chi-squared (v2) or
Fisher’s exact test was used. In addition, a v2 test and a
logistic regression were used to identify correlations
between the presence of adverse events and demographic
information and medical history, a paired t-test was utilized
to determine the difference between BP and pulse rate, a
t test was performed to analyze the difference between BP
and pulse rate related to demographic information and
medical history, and a multiple regression analysis was
conducted to investigate relevance. A linear mixed model
was analyzed to quantify the effects of fimasartan on the
differences in BP among various groups, including a group
that consisted of first-time hypertensive patients, a group
that was originally taking antihypertensive medications to
which fimasartan was added, and a group that ceased to
take the original hypertension medication and was given
fimasartan instead. To observe the effects of patient com-
pliance (whether patients took the drug) on the degree of
difference in BP, an analysis of covariance was conducted.
Frequency and percentage, which are descriptive statistics,
are presented according to the compliance rate, and a v2
test was used to determine the relevance between compli-




From May to August 2011, 14,151 Korean patients were
recruited from all operating internal medicine clinics in
Korea. A total of 50.7 % of the patients were male, the
average ± SD age was 59.0 ± 12.0 years, and the aver-
age ± SD BMI was 24.4 ± 2.9 kg/m2 (Table 1). The risk
factor frequencies were 44.6 % for old age ([60 years),
9.9 % for smoking, 37.6 % for obesity, 66.4 % for physical
inactivity, and 18.8 % for diabetes. Accompanying dis-
eases determined by individual doctors were stroke (1.6 %)
and ischemic heart disease (2.1 %; Table 1). The partici-
pant population included 37.9 % of new hypertension
patients initially treated with fimasartan (the naı¨ve group),
53.5 % of patients who switched to fimasartan from other
antihypertensive medications (the switched group), and
8.5 % of patients who had fimasartan added to their regi-
men due to uncontrollable BP (the add-on group; Table 1).
Of the concomitant antihypertensive medications, calcium
channel blockers (CCBs) were the most common, about
25 %.
3.2 Safety
Out of the 14,151 patients, 450 (3.31 %) complained of
adverse events after drug administration. Of the patients
who complained, approximately 333 (2.35 %) patients
were suspected of having a reaction related to the medi-
cation. The most frequent adverse events were dizziness
(1.55 %) and headache (0.52 %). Other symptoms included
fatigue, itching, abdominal pain, nausea, coughing, sleep
disorder, tachycardia, acroparesthesia, chest discomfort,
diarrhea, and back pain, but they occurred with very low
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frequency (Table 2). By indication, adverse effects were
3.42, 2.81, and 3.31 % in the naı¨ve patients, the switched
patients, and the add-on group, respectively. There were
168 cases (1.19 %) in which the patients stopped taking the
medication after the treatment had begun; in 135 of these
cases (0.95 % of all of the patients) the discontinuation was
related to the adverse effects of fimasartan. There was no
significant difference between the 60-mg (n = 10,543) and
120-mg (n = 3,608) groups, as the frequencies of adverse
events were 3.19 and 3.02 %, respectively (p = 0.66).
The adverse event profile was mostly not affected by
concomitant medication except that co-administration of a
b-blocker increased its frequency with an odds ratio of
1.757 (95 % CI 1.23–2.50). Even in occurrences of an
adverse event, in most cases (76.2 %) the symptoms resolved
without any special treatment, and no events that were
immediately life threatening or could cause death occurred.
3.3 Efficacy
Treatment with fimasartan for more than 2 months
decreased SBP by 18.7 ± 18.3 mmHg (from 145.4 ± 18.1
mmHg to 126.8 ± 12.6 mmHg), and DBP decreased by
9.7 ± 11.7 mmHg (from 88.7 ± 11.8 mmHg to 79.0 ±
8.7 mmHg) [all p \ 0.001] in all patients treated with 60
and 120 mg. The pulse rate decreased by 2.5 ± 7.9 beats/
min (from 74.4 ± 10.3 beats/min to 71.9 ± 9.2 beats/min)
[p \ 0.001; Table 3]. In the naı¨ve group, SBP decreased by
Table 1 Baseline
characteristics of patients




b Patients who were switched
from other antihypertensive
medication to fimasartan
c Patients who received add-on
antihypertensive therapy with
fimasartan
* p value B 0.01 between men
and women according to
Pearson v2 tests
ACEI angiotensin converting
enzyme inhibitor, BP blood
pressure, CCB calcium channel
blocker, DBP diastolic BP, SBP
systolic BP
Characteristic Men and women (n = 14,151) Men (n = 7,179) Women
(n = 6,972)
Age, y 59.0 ± 12.0 56.7 ± 11.9 61.5 ± 11.7*
Age [60 y, % 44.6 36.8 52.6*
Body weight, kg 64.88 ± 10.96 70.72 ± 9.97 58.8 ± 8.32*
Height, cm 162.8 ± 8.76 169.07 ± 6.38 156.27 ± 5.54*
Body mass index, kg/m2 24.38 ± 2.94 24.68 ± 2.75 24.07 ± 3.10*
Obesity, % 37.6 41.5 33.5
Physical inactivity, % 66.4 65.0 67.9
Smoking, % 1,406 (9.94) 1,310 (18.25) 96 (1.38)*
Alcohol use, % 3,508 (40.31) 2,859 (64.92) 649 (15.1)*
BP
SBP, mmHg 145.43 ± 18.07 146.2 ± 17.62 144.63 ± 18.5*
DBP, mmHg 88.71 ± 11.8 89.83 ± 11.86 87.56 ± 11.63*
Pulse rate, beats/min 74.38 ± 10.28 74.76 ± 10.55 73.98 ± 9.97*
Co-morbidity
Diabetes, % 18.8 19.4 18.2
Ischemic heart disease, % 2.1 1.7 2.4
Stroke, % 1.6 1.5 1.7
Concomitant medication
Antihypertensive drug
ACEI 295 (2.08) 161 (2.24) 134 (1.92)
b-blocker 809 (5.72) 394 (5.49) 415 (5.95)
CCB 3,472 (24.54) 181 (25.24) 1,660 (23.81)
Diuretic 1,320 (9.33) 615 (8.57) 705 (10.11)*
a-blocker 28 (0.2) 19 (0.26) 9 (0.13)
Other antihypertensive drug 388 (2.74) 198 (2.76) 190 (2.73)
Antiplatelet drug 2,641 (18.66) 1,308 (18.22) 1,333 (19.12)
Oral hypoglycemic drug 2,371 (16.75) 1,225 (17.06) 1,146 (16.44)
Insulin 131 (0.93) 67 (0.93) 64 (0.92)
Antidyslipidemic drug 2,848 (20.13) 1,352 (18.83) 1,496 (21.46)*
Anticoagulant 279 (1.97) 110 (1.53) 169 (2.42)
Indication, %
Naı¨vea 37.9 40.2 35.7
Changeb 53.5 51.2 56.0
Add-onc 8.5 8.6 8.4
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26.4 ± 17.3 mmHg (from 153.9 ± 15.5 mmHg to 127.4 ±
12.4 mmHg), and DBP decreased by 13.9 ± 11.6 mmHg
(from 93.8 ± 11.1 mmHg to 79.9 ± 8.7 mmHg). The
pulse rate was reduced by 3.2 ± 8.09 beats/min (from
75.5 ± 10.6 beats/min to 72.2 ± 9.4 beats/min) [all p \
0.001]. Furthermore, this group had a larger range of
reduction compared with the add-on and the switched
groups. The reduction in each group is depicted in Fig. 1.
Administration of 120 mg of fimasartan decreased SBP and
DBP by 20.1 ± 19.1 and 10.2 ± 12.4 mmHg, respectively,
which were significantly greater reductions than the
18.2 ± 18.0 mmHg (p \ 0.001) and 9.6 ± 11.4 mmHg
(p = 0.01) decreases observed with the 60-mg dose. The pulse
rate decreased more with the 120-mg dose than with the 60-mg
dose (2.9 ± 8.5 vs. 2.4 ± 7.6 beats/min, p \ 0.001; Table 4).
There were no significant differences when multiple
regression analyses were performed on the changes in BP
and the pulse rate based on demographic information and
medical history. However, as age increased, there were
larger changes in SBP and DBP (Table 5).
3.4 Responder Rate and Goal Rate
The responder rate (DBP to \90 mmHg or a reduction of
C10 mmHg) and the goal rate (combined SBP/DBP\140/
90 mmHg) were, respectively, 85.0 % and 75.6 % in the
naı¨ve patient group, 87.9 % and 74.5 % in the add-on
group, and 90.1 % and 79.7 % in the switched group. The
60-mg dose had better responder and goal rates than the
120-mg dose for the naı¨ve patient group and better goal
rates for the add-on group and the switched group (all
p \ 0.001; Table 6). Even after revising for age and sex,
SBP and DBP decreased when fimasartan was added (b -
Table 2 Adverse effects in patients taking fimasartan
Category Symptoms No. (%)
Skin and appendage disorders Skin rash 2 (0.38)





Toenail hemorrhage 1 (0.19)
Cold sweating 1 (0.19)
Musculoskeletal system
disorders




Back pain 4 (0.75)










Bitter taste 1 (0.19)
Vision disorders Visual disturbance 1 (0.19)



















Epigastric soreness 2 (0.38)






Low blood pressure 7 (1.32)
Hypertension 3 (0.56)




Vascular disorders Palpitation 5 (0.94)
Varicose vein 1 (0.19)
Table 2 continued
Category Symptoms No. (%)
Respiratory disorders Asthma 1 (0.19)
Dyspnea 3 (0.56)
Sputum 1 (0.19)
Shortness of breath 4 (0.75)
Reproductive disorders Coughing 14 (2.64)
Body as a whole – general
disorders
Erectile insufficiency 2 (0.38)
Fatigue 18 (3.39)
Anorexia 2 (0.38)
Weight loss 2 (0.38)
Dry mouth 1 (0.19)
Facial edema 3 (0.56)
Ankle edema 1 (0.19)
Others 8 (1.51)
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21.7/-10.3; all p \ 0.001), and the patients who switched
to fimasartan also exhibited decreases in SBP and DBP
values (b -12.4/-6.3, all p \ 0.001).
3.5 Compliance
The compliance of the patients with the drug was calcu-
lated by dividing the actual number used or consumed by
the planned number of administrations. Overall, drug
compliance was very high; excellent compliance was at
68.1 %, very good compliance was at 26.9 %, good com-
pliance was at 3.4 %, and poor compliance was at 1.7 %
(Table 7). A higher compliance rate resulted in larger
effects on DBP and SBP (Table 8).
4 Discussion
This study was conducted approximately 2–3 months after
the launch of fimasartan, the ninth ARB to be developed, to
investigate its safety and efficacy in a realistic clinical
setting. Although there was no direct comparison between
conventional ARBs and fimasartan, the efficacy of fima-
sartan at a dose of either 60 or 120 mg once daily appeared
to be excellent, and side effects were minimal. Further-
more, fimasartan had a powerful effect in decreasing BP,
and the efficacy and adverse event profile were unaffected
by age, sex, or the presence of diabetes or concomitant
disease, such as heart and brain diseases, and in particular
not by concomitant medication.
4.1 Safety and Tolerability
ARBs are widely preferred over other antihypertensive
medications because of their placebo-like tolerability [19].
As such, this study exhibited a rate of adverse events
related to the medication of approximately 2.35 %, and no
life-threatening adverse reactions were noted. This low
adverse event rate improves treatment tolerability; the
administration of fimasartan had a 0.95 % early
Table 3 Blood pressure
response before and after more
than 2 months’ treatment with
fimasartan (60 and 120 mg) in
all patients
DBP diastolic blood pressure,
SBP systolic blood pressure,
* p \ 0.0001 versus
pretreatment values
Patients Before treatment After treatment Difference
Men and women
SBP, mmHg 145.43 ± 18.07 126.77 ± 12.61 -18.65 ± 18.29*
DBP, mmHg 88.71 ± 11.80 78.98 ± 8.66 -9.73 ± 11.67*
Pulse rate, beats/min 74.38 ± 10.28 71.88 ± 9.19 -2.5 ± 7.85
Men
SBP, mmHg 146.20 ± 17.62 127.49 ± 12.63 -18.71 ± 17.62*
DBP, mmHg 89.83 ± 11.86 79.78 ± 8.83 -10.05 ± 11.67*
Pulse rate, beats/min 74.76 ± 10.55 72.21 ± 9.40 -2.55 ± 8.07*
Women
SBP, mmHg 144.63 ± 18.50 126.03 ± 12.55 -18.60 ± 18.96*
DBP, mmHg 87.56 ± 11.63 78.16 ± 8.41 -9.39 ± 11.65*


































Fig. 1 Changes in systolic (SBP) and diastolic (DBP) blood pressure
in all patients treated with 60 and 120 mg of fimasartan








D SBP, mmHg -18.16 ± 17.97 -20.10 ± 19.14 \.0001
D DBP, mmHg -9.57 ± 11.40 -10.17 ± 12.41 0.0103
D Pulse rate, beats/min -2.36 ± 7.62 -2.91 ± 8.47 0.0005
Men
D SBP, mmHg -18.23 ± 17.37 -19.93 ± 18.22 0.0003
D DBP, mmHg -10.00 ± 11.45 -10.17 ± 12.22 0.5796
D Pulse rate, beats/min -2.37 ± 7.78 -3.00 ± 8.76 0.0050
Women
D SBP, mmHg -18.09 ± 18.53 -20.31 ± 20.23 \.0001
D DBP, mmHg -9.16 ± 11.32 -10.17 ± 12.65 0.0039
D Pulse rate, beats/min -2.34 ± 7.45 -2.79 ± 8.11 0.0456
D indicates change, DBP diastolic blood pressure, SBP systolic blood
pressure, * p-value between 60 versus 120 mg
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termination rate in the study. Although this study is an
observational study, considering that the discontinuation
rates are in the range of 2.5–9.3 % for other hypertension
medications [20] and are 2.3 %, 2.4 %, and 3.3 % for the
widely used ARBs losartan, candesartan, and irbesartan,
respectively [21, 22], the 0.95 % rate for fimasartan is
markedly lower. When compared with the discontinuation
rate of 1.1–2.1 % for azilsartan medoxomil and 1.1–6.1 %
for valsartan (320 mg) [23], the rate for fimasartan is still
very low. The most common side effect related to fima-
sartan in this study was dizziness, which can be attributed
to the powerful and rapid decrease in BP; there was no
difference in the incidence of dizziness between the 60-mg
and 120-mg groups. Dizziness occurred more often in the
ARB group than in the placebo group, and episodes of
documented hypotension did not occur as frequently as
expected. Future research is needed to ascertain the effi-
cacy and tolerability of low-dose fimasartan (a half-dose of
60 mg, the smallest dose currently available).
In this study, dizziness occurred at a rate of 3.48 % for
patients under 60 years of age and 2.78 % for patients over
60 years of age, which is thought to imply that the
Table 5 Multiple regression analysis on blood pressure (BP) reductions, using baseline BP, age, sex, and other co-morbidities
Variable DSBP DDBP DPR
b SE(b) P value b SE(b) P value b SE(b) P value
Women -0.42 1.67 0.801 1.27 1.02 0.211 1.49 0.64 0.021
Age 0.18 0.07 0.007 0.12 0.04 0.004 0.00 0.03 0.972
History of cardiovascular disease 4.57 2.38 0.055 2.42 1.45 0.096 3.06 0.92 0.001
Smoking 2.05 2.06 0.321 2.10 1.26 0.095 0.98 0.79 0.215
High BMI -2.19 1.60 0.172 -0.94 0.98 0.335 -0.95 0.62 0.121
Abdominal obesity -0.62 1.64 0.703 -0.25 1.00 0.801 0.61 0.63 0.335
Physical inactivity 0.56 1.48 0.706 -0.04 0.90 0.962 0.32 0.57 0.570
Diabetes 0.10 2.24 0.965 0.23 1.36 0.865 -1.91 0.86 0.027
Dyslipidemia 1.61 1.54 0.297 1.06 0.94 0.260 -1.12 0.59 0.059
Family history of hypertension 1.64 1.76 0.351 0.17 1.07 0.874 -0.46 0.68 0.498
Renal dysfunction -2.76 2.84 0.331 -0.61 1.73 0.725 -1.46 1.09 0.181
Sleep apnea 0.20 2.10 0.925 -1.20 1.28 0.352 -0.33 0.81 0.683
R2 0.02 0.02 0.017
D indicates change, BMI body mass index, SE standard error
Table 6 Responder and goal rates with fimasartan 60 and 120 mg
Variable 60 mg 120 mg Both
Responder rate
Naı¨vea 86.1 81.2* 85.0
Add-onb 88.3 86.9 87.9
Switchc 90.9 87.7 90.1
Goal rate
Naı¨vea 77.7 68.4* 75.6
Add-onb 77.9 65.3* 74.5
Switchc 81.7 74.4* 79.7
Data are given as percent
a Patients who had never received any antihypertensive medication
and received fimasartan
b Patients who were switched from other antihypertensive medication
to fimasartan
c Patients who received add-on antihypertensive therapy with
fimasartan
* p \ 0.001 versus 60 mg according to the v2 test
Table 7 Overall drug compliance
Compliance rate Men Women Men and women
Excellent (100 %) 67.0 69.2 68.1
Very good (90*99 %) 27.5 26.2 26.9
Good (80*89 %) 3.8 3.0 3.4
Poor (\80 %) 1.7 1.7 1.7
Table 8 Blood pressure changes according to compliancea
Compliance
rate
D SBP D DBP
b SE(b) P value b SE(b) P value
Excellent
(100 %)
-10.8 0.77 \0.001 -5.33 0.52 \0.001
Very good
(90*99 %)
-10.9 0.79 \0.001 -5.29 0.53 \0.001
Good
(80*89 %)




a Analysis of covariance, based on poor compliance
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medication is more effective in lowering the BP for
patients under 60 years of age. However, there was no
difference in the frequency of dizziness in patient groups
above or below 75 years of age (p = 0.553, data not
shown). Therefore, the administration of the medication is
safer in an older population, regardless of the dosage. As
this is an important issue, it certainly requires further
investigation.
In a previous study, the frequency of cough related to an
ARB was no higher than the frequency in the placebo
group, but it was significantly lower compared with the
angiotensin-converting enzyme inhibitor (ACEI) group
[19]. This study had a low frequency of cough (2.9 %) that
did not cause discontinuation of the medication. The fre-
quency of angioedema also occurred less frequently at
0.1–0.2 % when taking an ARB compared with an ACEI
[24, 25]. Therefore, for a patient who experiences angio-
edema due to ACEI treatment, an ARB is recommended as
an alternative medication [26].
4.2 Efficacy
For hypertensive patients with little fluctuation in the actual
degree of BP change according to different ARB formu-
lations, the average SBP and DBP values decrease
approximately 10 and 5 mmHg, respectively, after
administration of the recommended daily dose of an ARB
[27, 28]. Aside from the powerful antihypertensive prop-
erty of fimasartan, this can also be attributed to the fact that
the participants in this study were relatively young, low-
risk hypertension patients with no complications such as
stroke or diabetes. It can also be attributed to the fact that
this study targeted hypertensive patients who visited pri-
mary-care clinics. We found that there was a large decrease
in SBP/DBP in the naı¨ve group relative to the other two
groups. It is difficult to say whether this is unique to this
drug or whether this depends on the patient population in
this observational study. One possible explanation for those
differences is that BP before fimasartan treatment in the
naı¨ve group was higher than that in the other two groups
(about 15 mmHg in the switch group, and about 4.4 mmHg
in the add-on group). This is because higher BP at baseline
usually shows a larger reduction.
This study was conducted using two drug doses, 60 and
120 mg; the higher dose group showed a slightly greater
decrease in SBP of 1.9 mmHg. As in most clinical trials
evaluating ARBs, this study did not result in greatly dif-
ferent changes in BP due to the dose of the medication. In
fact, a study involving the most recently developed ARB,
azilsartan, showed no difference in BP over a wide dose
range of 5–80 mg, nor did the capacity to control BP
improve [29]. Another interesting fact observed in this
study was a significant decrease in the pulse rate after
administration of fimasartan, which can lead to the possi-
bility of fimasartan blocking the sympathetic nervous sys-
tem (SNS), similar to the effects of blocking the renin-
angiotensin-aldosterone system (RAAS) and the SNS, as
observed with eprosartan [30]. Angiotensin (Ang) II stim-
ulates the SNS, and the SNS stimulates the secretion of
renin and Ang II. Hence, inhibition of Ang II activity might
decrease the activity of the SNS. This probably explains a
decrease in pulse rate with fimasartan. This hypothesis
needs to be supported with experimental studies and
comparative clinical trials in the future.
4.3 Responder and Goal Rates
A responder was defined as having a DBP\90 mmHg or a
DBP reduction of C10 mmHg; the responder rate was very
high, as it nearly reached 85–90 %. It is possible that the
120-mg dosage group had a lower responder rate than the
60-mg dosage group because of the difference in BP at the
beginning of treatment. The baseline SBP of the patients
receiving 120 mg was almost 5 mmHg higher but the
difference in BP between the 60 and 120 mg doses was
only 2 mmHg after treatment. The goal rate of having a
combined SBP and DBP below 140/90 mmHg was excel-
lent at approximately 76.6 %, similar to the responder rate.
Particularly among patients whose BPs could not be con-
trolled with conventional antihypertensive medications,
those who switched to or added fimasartan displayed sig-
nificant effects of fimasartan and high rates of reaching the
goal BP.
4.4 Compliance
ARB medication has a relatively low occurrence of adverse
events compared to ACEIs. This low adverse event rate
results in increased compliance among hypertensive
patients, which, in turn, makes controlling their BP more
feasible. For this reason, ultimately, ARB medication is
thought to contribute to lowering the incidence and mor-
tality rates associated with cardiovascular diseases. In this
study, patient compliance was calculated by dividing the
actual number used or consumed by the planned number of
administrations. Approximately 95 % of the entire patient
population accounted for the fimasartan patient compliance
rate of 90 %, which is an outstanding result compared to
those of the study conducted by Wogen et al., who com-
pared amlodipine, lisinopril, and valsartan in participants in
a similar age group [31]. It was found that a higher com-
pliance rate resulted in a larger decrease in BP. When
persistence was established (when 95 % of the population
was continuously given the medication), fimasartan was
found to be superior to the 70–80 % rate at 2 months
reported in another study [31]. According to a study that
54 J. B. Park et al.
explored ACEIs and compliance rates for ARBs, the
compliance rates of conventional ACEIs and ARBs were
approximately 88 % [32]. In general, it is known that drug
compliance is directly associated with a decrease in BP and
a decrease in the incidence of cardiovascular events. The
overall compliance with treatment with fimasartan in this
study was extremely high, and the lowest compliance rate
out of the four compliance rates accounted for only 1.7 %
of the overall population. Furthermore, similar to the
previous studies, decreases in the DBP and SBP values in
this study were found to be larger when compliance was
better. Therefore, the results indicate that fimasartan
increases the compliance of patients with the treatment
and improves the rate at which BP is controlled because it
has powerful antihypertensive properties and minimal
adverse reactions.
4.5 Limitations
There were a few limitations in this study. First, it is not
certain whether the results can be generalized and applied
to other ethnic groups, as this trial was performed only by
primary-care physicians in Korea. However, similar results
can be expected in other ethnic groups, considering that the
research on ARBs conducted in Western countries identi-
fied effects analogous to those in Korea and Asia [6].
Second, the accuracy of the study results may be ques-
tioned because this was a post-marketing observational
study that did not have established inclusion or exclusion
guidelines and was an open-label, observational study that
relied on doctors’ decisions for patient inclusion. However,
this type of study design enabled the inclusion of a more
diverse participating population and reflected the actual
clinical situation more accurately and realistically. Third,
the study was not able to verify whether the patients
actually took the medication, as the study only depended
on an analysis of patients’ recall. However, previous vali-
dation studies have found good correlations between pre-
scription claims and actual drug use [33], and this study
found that the rate of drug consumption correlated well
with patients’ verbal responses. Therefore, it is believed
that there should not be a large discrepancy between pre-
scription claims and actual drug use in this study.
5 Conclusion
Fimasartan, the ninth ARB to be developed, has minimal
side effects, high overall patient compliance, and an evi-
dent effect on decreasing BP. Accordingly, we believe that
fimasartan can be used safely because its effectiveness and
side effects did not differ significantly according to sex,
age, and concomitant disease.
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